Clinical trials of EGFR-TKI with nanoparticle in lung cancer. In August 2020, a clinical trials.gov advanced search for “nanoparticles and lung cancer” was conducted. These were evaluated and chosen based on the study’s current status.
| Sr. No. | Clinical trial | Study type | Description | Status |
|---|---|---|---|---|
| 1 | NCT00553462 | Phase II | This phase II trial is studying how well giving carboplatin and paclitaxel albumin-stabilized nanoparticle formulation together with radiation therapy and erlotinib works in treating patients with stage III NSCLC that cannot be removed by surgery. | Completed |
| 2 | NCT04486833 | Phase I–II | Safety and efficacy of GPX-001 + osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. | Recruiting |